Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Engagement of the OX-40 receptor in vivo enhances antitumor immunity
Autore:
Weinberg, AD; Rivera, MM; Prell, R; Morris, A; Ramstad, T; Vetto, JT; Urba, WJ; Alvord, G; Bunce, C; Shields, J;
Indirizzi:
Robert W Franz Canc Res Ctr, Earle A Chiles Res Inst, Prov Portland Med Ctr, Portland, OR 97213 USA Robert W Franz Canc Res Ctr Portland OR USA 97213 Portland, OR 97213 USA Oregon Hlth Sci Univ, Dept Surg, Sect Surg Oncol, Portland, OR 97201 USA Oregon Hlth Sci Univ Portland OR USA 97201 Oncol, Portland, OR 97201 USA Cantab Pharmaceut, Cambridge, England Cantab Pharmaceut Cambridge England ntab Pharmaceut, Cambridge, England NCI, Comp Serv, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA NCIFrederick MD USA 21702 ck Canc Res & Dev Ctr, Frederick, MD 21702 USA NCI, Stat Serv, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA NCIFrederick MD USA 21702 ck Canc Res & Dev Ctr, Frederick, MD 21702 USA
Titolo Testata:
JOURNAL OF IMMUNOLOGY
fascicolo: 4, volume: 164, anno: 2000,
pagine: 2160 - 2169
SICI:
0022-1767(20000215)164:4<2160:EOTORI>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
T-CELL ACTIVATION; COLONY-STIMULATING FACTOR; OX40 LIGAND; IN-VIVO; DENDRITIC CELLS; TUMOR-CELLS; AUTOIMMUNE ENCEPHALOMYELITIS; B7 COSTIMULATION; LYMPH-NODES; SPINAL-CORD;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
55
Recensione:
Indirizzi per estratti:
Indirizzo: Weinberg, AD Robert W Franz Canc Res Ctr, Earle A Chiles Res Inst, Prov Portland Med Ctr, 4805 NE Glisan, Portland, OR 97213 USA Robert W Franz Canc Res Ctr 4805 NE Glisan Portland OR USA 97213
Citazione:
A.D. Weinberg et al., "Engagement of the OX-40 receptor in vivo enhances antitumor immunity", J IMMUNOL, 164(4), 2000, pp. 2160-2169

Abstract

The OX-40 receptor (OX-40R), a member of the TNFR family, is primarily expressed on activated CD4(+) T lymphocytes. Engagement of the OX-40R, with either OX-40 ligand (OX-40L) or an Ab agonist, delivers a strong costimulatory signal to effector T cells. OX-40R(+) T cells isolated from inflammatory lesions in the CNS of animals with experimental autoimmune encephalomyelitis are the cells that respond to autoantigen (myelin basic protein) in vivo. We identified OX-40R(+) T cells within primary tumors and tumor-invaded lymph nodes of patients with cancer and hypothesized that they are the tumor-Ag-specific T cells. Therefore, we investigated whether engagement of the OX-40R in vivo during tumor priming would enhance a tumor-specific T cell response. Injection of OX-40L:Ig or anti-OX-40R in vivo during tumor priming resulted in a significant improvement in the percentage of tumor-free survivors (20-55%) in four different murine tumors derived from four separate tissues. This anti-OX-40R effect was dose dependent and accentuated tumor-specific T cell memory. The data suggest that engagement of the OX-40R in vivoaugments tumor-specific priming by stimulating/expanding the natural repertoire of the host's tumor-specific CD4(+) T cells. The identification of OX-40R(+) T cells clustered around human tumor cells in vivo suggests that engagement of the OX-40R may be a practical approach for expanding tumor-reactive T cells and thereby a method to improve tumor immunotherapy in patients with cancer.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/07/20 alle ore 18:02:30